BRPI0514891A - composição contendo derivados de prostaglandina e uso da referida composição - Google Patents

composição contendo derivados de prostaglandina e uso da referida composição

Info

Publication number
BRPI0514891A
BRPI0514891A BRPI0514891-0A BRPI0514891A BRPI0514891A BR PI0514891 A BRPI0514891 A BR PI0514891A BR PI0514891 A BRPI0514891 A BR PI0514891A BR PI0514891 A BRPI0514891 A BR PI0514891A
Authority
BR
Brazil
Prior art keywords
composition
human subject
effective
composition containing
subject
Prior art date
Application number
BRPI0514891-0A
Other languages
English (en)
Inventor
Ryuji Ueno
Original Assignee
Sucampo Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35229739&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0514891(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sucampo Ag filed Critical Sucampo Ag
Publication of BRPI0514891A publication Critical patent/BRPI0514891A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/94—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

COMPOSIçãO CONTENDO DERIVADOS DE PROSTAGLANDINA E USO DA REFERIDA COMPOSIçãO A presente invenção refere-se a um método para o tratamento de longo prazo de distúrbios gastrointestinais em um sujeito humano, o qual compreende administrar uma quantidade eficaz de um composto de prostaglandina halogenado e/ou seu tautómero ao sujeito. O método não induz substancialmente mudança de eletrólito durante o tempo do tratamento. O composto usado na presente invenção pode melhorar a qualidade de vida em um sujeito humano com distúrbios gastrointestinais, é similarmente eficaz no tratamento de sujeitos humanos do sexo masculino e feminino, e também eficaz em um sujeito humano com até mesmo 65 anos de idade ou mais.
BRPI0514891-0A 2004-09-02 2005-09-01 composição contendo derivados de prostaglandina e uso da referida composição BRPI0514891A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US60652104P 2004-09-02 2004-09-02
US66631705P 2005-03-30 2005-03-30
US66659305P 2005-03-31 2005-03-31
PCT/JP2005/016464 WO2006025599A1 (en) 2004-09-02 2005-09-01 Prostaglandin derivatives for treating gastrointestinal disorder

Publications (1)

Publication Number Publication Date
BRPI0514891A true BRPI0514891A (pt) 2008-06-24

Family

ID=35229739

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0514891-0A BRPI0514891A (pt) 2004-09-02 2005-09-01 composição contendo derivados de prostaglandina e uso da referida composição

Country Status (16)

Country Link
US (2) US8748481B2 (pt)
EP (1) EP1791545B1 (pt)
JP (4) JP2008511541A (pt)
KR (4) KR20170003712A (pt)
CN (1) CN102885821A (pt)
AR (1) AR050626A1 (pt)
AU (1) AU2005278323B2 (pt)
BR (1) BRPI0514891A (pt)
CA (1) CA2577284A1 (pt)
ES (1) ES2603381T3 (pt)
IL (1) IL181332A (pt)
MX (1) MX2007002602A (pt)
NO (1) NO340989B1 (pt)
NZ (1) NZ553434A (pt)
TW (1) TWI387454B (pt)
WO (1) WO2006025599A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2379652T3 (es) * 2002-10-23 2012-04-30 Sucampo Ag Compuestos de prostaglandina para el tratamiento de obesidad
WO2005002588A1 (en) * 2003-07-03 2005-01-13 Sucampo Ag Enteric coated composition comprising prostaglandin analogs as chloride channel opener
NZ570190A (en) 2006-01-24 2011-03-31 Sucampo Ag Pharmaceutical composition comprising a bi-cyclic compound and method for stabilizing the bi-cyclic compound
US20090030072A1 (en) * 2007-07-03 2009-01-29 Sucampo Ag Pharmaceutical combination of opioid and prostaglandin compound
CN108685929A (zh) * 2012-04-23 2018-10-23 苏坎波公司 用于治疗具有腹泻的肠易激综合征的方法
US10022389B2 (en) * 2013-02-04 2018-07-17 Taisho Pharmaceutical Co., Ltd. Prophylactic or therapeutic drug for constipation
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5428062A (en) 1987-01-28 1995-06-27 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti ulcers containing same
US5166174A (en) 1987-01-28 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti-ulcers containing same
US5225439A (en) 1987-01-28 1993-07-06 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti ulcers containing same
US5317032A (en) * 1987-10-02 1994-05-31 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Prostaglandin cathartic
PT1220849E (pt) 1999-10-15 2004-10-29 Sucampo Ag Composicao de compostos biciclicos e metodo para a sua estabilizacao
US6414016B1 (en) * 2000-09-05 2002-07-02 Sucampo, A.G. Anti-constipation composition
TWI302100B (en) * 2001-05-02 2008-10-21 Sucampo Ag Composition for treating drug-induced constipation
AR035242A1 (es) 2001-05-18 2004-05-05 Sucampo Ag Uso de un lipido bioactivo halogenadopara preparar una composicion catartica y compuesto lipido bioactivo halogenado
AU2002330747B2 (en) * 2001-08-31 2007-07-19 Sucampo Ag Prostaglandin analogs as chloride channel opener
TWI331920B (en) * 2001-11-14 2010-10-21 Sucampo Ag Unit dosage form for relieving or treating constipation in human patients
TWI263505B (en) 2001-11-19 2006-10-11 Sucampo Ag Pharmaceutical composition comprising a C1C-2 channel opener
CN1753680B (zh) * 2002-12-27 2010-12-08 苏坎波公司 用于治疗腹部不适的前列腺素衍生物
WO2005002588A1 (en) 2003-07-03 2005-01-13 Sucampo Ag Enteric coated composition comprising prostaglandin analogs as chloride channel opener

Also Published As

Publication number Publication date
JP2018150354A (ja) 2018-09-27
NO340989B1 (no) 2017-07-31
IL181332A (en) 2015-09-24
TWI387454B (zh) 2013-03-01
AU2005278323B2 (en) 2011-03-17
JP6408426B2 (ja) 2018-10-17
US20140315994A1 (en) 2014-10-23
KR20180033310A (ko) 2018-04-02
AR050626A1 (es) 2006-11-08
KR20070048221A (ko) 2007-05-08
US20060063830A1 (en) 2006-03-23
AU2005278323A1 (en) 2006-03-09
KR20140019006A (ko) 2014-02-13
MX2007002602A (es) 2007-04-25
IL181332A0 (en) 2007-07-04
EP1791545B1 (en) 2016-08-31
WO2006025599A1 (en) 2006-03-09
JP2013049688A (ja) 2013-03-14
JP2015166377A (ja) 2015-09-24
ES2603381T3 (es) 2017-02-27
KR20170003712A (ko) 2017-01-09
EP1791545A1 (en) 2007-06-06
CN102885821A (zh) 2013-01-23
NO20071704L (no) 2007-05-31
TW200612901A (en) 2006-05-01
JP2008511541A (ja) 2008-04-17
NZ553434A (en) 2010-01-29
US8748481B2 (en) 2014-06-10
CA2577284A1 (en) 2006-03-09

Similar Documents

Publication Publication Date Title
BRPI0514891A (pt) composição contendo derivados de prostaglandina e uso da referida composição
Peters Biochemical Lesions and Lethal Synthesis: International Series of Monographs on Pure and Applied Biology: Modern Trends in Physiological Sciences
JP5827326B2 (ja) リン酸輸送を阻害する化合物及び方法
NO20071042L (no) 5-substituerte 2-fenylaminobenzamider som MEK-inhibitorer
BR0308816A (pt) Tiazolidina-4-carbonitrilas e análogos e seus usos como inibidores da dipeptil-peptidas
NO20064982L (no) 1,3,4-oksadiazol-2-oner som PPAR delta modulatorer og anvendelse derav
Caserio Treatment of alopecia areata with squaric acid dibutylester
BR9807950A (pt) Composto, composição farmacêutica, uso de um composto, e, processos para tratar ou reduzir o risco de doenças ou condições humanas, o risco de doença inflamatória o risco da dor e para a preparação de um composto
Soto et al. c-Fos activity in the insular cortex, nucleus accumbens and basolateral amygdala following the intraperitoneal injection of saccharin and lithium chloride
BR9914266A (pt) Derivados de propanolamina substituìdos por heterociclos, processos para a sua preparação, medicamentos contendo estes compostos e seu emprego
CY1112638T1 (el) Χρηση των παραγωγων ινδολιου ως ενεργοποιητες νurr-1 για την θεραπεια νοσου ραrκινsον
BR0215904A (pt) Métodos e composições para prover glutamina
HK1110768A1 (en) 5,6,7-trihydroxyheptanoic acid and analogs for the treatment of ocular diseases and diseases associated with hyperproliferative and angiogenic responses
BR0311363A (pt) Formulação farmacêutica de liberação imediata, uso da mesma, e, método para tratar um distúrbio cardiovascular em um paciente
KR970706282A (ko) 2, 7-치환된 옥타하이드로-1H-피리도[1, 2-a]피라진 유도체(2, 7-SUBSTITUTED OCTAHYDRO-1H-PYRIDO[1, 2-a]PYRAZINE DERIVATIVES)
BR112022004587A2 (pt) Métodos para tratar narcolepsia tipo 1, diminuir eventos tipo cataplexia, aumentar concentração de cálcio intracelular, aumentar latência de sono em manutenção de teste de insônia, melhorar classificação de escaça de sonolência de karolinska, tratar uma doença associada a nível de orexina reduzido, aumentar alerta, melhorar classificação de escala de sonolência epworth, e, composição farmacêutica
Spiller The symptom-complex of occlusion of the posterior inferior cerebellar artery: two cases with necropsy
MX2024004131A (es) Ciertos 2,5-diazabiciclo[4.2.0]octanos como moduladores del receptor de glp-1.
NO971899D0 (no) Anvendelse av £R-(Z)|-<alfa>-(metoksyimino)-<alfa>-(1 azabicyklo £2.2.2| okt-3-yl) acetonitril til å redusere amyloid <beta>-A4-dannelse hos Alzheimer's sykdom
TW200724138A (en) Substituted carboxylic acid derivatives for the treatment of diabetes and lipid disorders, their preparation and use
KR20120081151A (ko) 통증 조절 및 탈수초 손상의 역전에서의 ｎ?2?하이드록시?에틸?피페라진?ｎ‘?2?에탄 설폰산（ｈｅｐｅｓ）의 역할
ATE44875T1 (de) 4-amino-2-(imidazolidin-2-on-l-yl)-pyrimidin-5carbons|ure-(n-(3-trifluormethyl-phenyl)-amide) zur antithrombotischen prophylaxe und behandlung sowie ihre verwendung zur herstellung von antithrombotisch wirksamen arzneimitteln.
Wadhwa The history of drug development in psychiatry: a lesson in serendipity
KR950032191A (ko) 사이클로헥산 유도체, 이의 제조방법 및 질병을 치료하기 위한 화합물의 용도
BR9813020A (pt) Utilização de derivados de ácido lisofosfatidìlico, compostos e drogas que contém esses compostos

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]